{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T20:54:15Z","timestamp":1770411255010,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Geriatric Pharmacotherapy"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.amjopharm.2005.02.001","type":"journal-article","created":{"date-parts":[[2005,8,20]],"date-time":"2005-08-20T03:05:29Z","timestamp":1124507129000},"page":"1-7","source":"Crossref","is-referenced-by-count":42,"title":["Is donepezil therapy associated with reduced mortality in nursing home residents with dementia?"],"prefix":"10.1016","volume":"3","author":[{"given":"Mason C.","family":"Gasper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian R.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate L.","family":"Lapane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjopharm.2005.02.001_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1212\/WNL.56.9.1154","article-title":"Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"56","author":"Doody","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/archneur.61.2.252","article-title":"The cognitive benefits of galantamine are sustained for at least 36 months: A long-term extension trial","volume":"61","author":"Raskind","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archneur.58.3.427","article-title":"Open-label multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease","volume":"58","author":"Doody","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archneur.60.6.843","article-title":"Analysis of outcome in retrieved dropout patients in rivastigmine vs placebo, 26-week, Alzheimer disease trial","volume":"60","author":"Farlow","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib5","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1176\/appi.ajp.160.11.2003","article-title":"Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease","volume":"160","author":"Krishnan","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib6","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0024-3205(03)00083-3","article-title":"The nonneuronal cholinergic system in humans: Expression, function, and pathophysiology","volume":"72","author":"Wessler","year":"2003","journal-title":"Life Sci"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1532-5415.2002.50005.x","article-title":"Tacrine therapy is associated with reduced mortality in nursing home residents with dementia","volume":"50","author":"Ott","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/WNL.58.1.62","article-title":"Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare","volume":"58","author":"Hill","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib9","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1532-5415.2001.49266.x","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezll in patients with Alzheimer's disease in the nursing home setting","volume":"49","author":"Tariot","year":"2001","journal-title":"J Am Geriatr Soc"},{"issue":"Suppl 1","key":"10.1016\/j.amjopharm.2005.02.001_bib10","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0197-4580(00)82677-9","article-title":"Epidemiology of Alzheimer's disease","volume":"21","author":"Katzman","year":"2000","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib11","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"Long-term donepezll treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial","volume":"363","author":"Courtney","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1212\/WNL.47.1.166","article-title":"Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality, Tacrine Study Group","volume":"47","author":"Knopman","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp.72.3.310","article-title":"Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease","volume":"72","author":"Lopez","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib14","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1046\/j.1365-2389.2003.51306.x","article-title":"Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease","volume":"51","author":"Geldmacher","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF03324534","article-title":"Donepezil use in US nursing homes","volume":"16","author":"Pedone","year":"2004","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1212\/WNL.52.2.238","article-title":"Tacrine use in nursing homes: Implications for prescribing new cholinesterase inhibitors","volume":"52","author":"Gifford","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1532-5415.1998.tb02553.x","article-title":"The SAGE database: Introducing functional outcomes in geriatric pharmacoepidemiology","volume":"46","author":"Bernabei","year":"1998","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib18","doi-asserted-by":"crossref","first-page":"M25","DOI":"10.1093\/gerona\/54.1.M25","article-title":"Characteristics of the SAGE database: A new resource for research on outcomes in long-term care","volume":"54","author":"Bernabei","year":"1999","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001191","article-title":"Donepezil for mild and moderate Alzheimer's disease","volume":"2","author":"Birks","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib20","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1093\/geronb\/50B.1.P1","article-title":"The structure of social engagement among nursing home residents","volume":"50","author":"Mor","year":"1995","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib21","doi-asserted-by":"crossref","first-page":"M174","DOI":"10.1093\/geronj\/49.4.M174","article-title":"MDS Cognitive Performance Scale","volume":"49","author":"Morris","year":"1994","journal-title":"J Gerontol"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib22","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1532-5415.1994.tb06984.x","article-title":"The MDS Cognition Scale: A valid instrument for identifying and staging nursing home residents with dementia using the minimum data set","volume":"42","author":"Hartmaier","year":"1994","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib23","doi-asserted-by":"crossref","first-page":"M128","DOI":"10.1093\/gerona\/50A.2.M128","article-title":"Validation of the Minimum Data Set Cognitive Performance Scale: Agreement with the Mini-Mental State Examination","volume":"50","author":"Hartmaier","year":"1995","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00005650-199802000-00006","article-title":"Validity of diagnostic and drug data in standardized nursing home resident assessments: Potential for geriatric pharmacoepidemiology","volume":"36","author":"Gambassi","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib25","first-page":"A450","article-title":"Rivastigmine provides symptomatic benefit in dementia with Lewy bodies: Findings from a placebo-controlled international multicenter study","volume":"54","author":"McKeith","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib26","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/jnnp.72.6.708","article-title":"Donepezil for cognitive impairment in Parkinson's disease: A randomized controlled study","volume":"72","author":"Aarsland","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/01.WNL.0000078943.50032.FC","article-title":"Donepezil in vascular dementia: A randomized, placebo-controlled study","volume":"61","author":"Wilkinson","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib28","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/WNL.55.12.1863","article-title":"Research tvaluation and diagnosis of possible Alzheimer's disease over the last two decades: II","volume":"55","author":"Lopez","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib29","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib30","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1532-5415.2004.t01-1-52379_12.x","article-title":"Mortality in donepezil-treated patients","volume":"52","author":"Geldmacher","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib31","series-title":"The Moral Challenge of Alzheianer Disease","first-page":"76","article-title":"Quality of life: Issues in the cultural perception of dementia","author":"Post","year":"1995"},{"key":"10.1016\/j.amjopharm.2005.02.001_bib32","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archneur.56.10.1266","article-title":"Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease","volume":"56","author":"Lopez","year":"1999","journal-title":"Arch Neurol"}],"container-title":["The American Journal of Geriatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594605000115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594605000115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T18:27:02Z","timestamp":1548181622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1543594605000115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S1543594605000115"],"URL":"https:\/\/doi.org\/10.1016\/j.amjopharm.2005.02.001","relation":{},"ISSN":["1543-5946"],"issn-type":[{"value":"1543-5946","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}